Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Través, Paqui G ^a   Luque, Alfonso ^b   Hortelano, Sonsoles ^c  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD163 ANTIGEN; CHITINASE; CXCL9 CHEMOKINE; EOTAXIN 2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; OSTEONECTIN; PROTEIN P53; T LYMPHOCYTE RECEPTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VASCULOTROPIN; AUTACOID; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; METASTASIS; MOLECULAR BIOLOGY; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MACROPHAGE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; IMMUNE TOLERANCE; INFLAMMATION MEDIATORS; MACROPHAGES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

MLCS; MLOWN;

EID: 84872149730     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/568783     Document Type: Article

References (133)

1. Ehrlich P., Ueber den jetzigen Stand der Karzinomforschung. Nederlands Tijdschrift voor Geneeskunde 1909 5 273 290
2. Burnet F. M., Immunological surveillance in neoplasia. Transplantation reviews 1971 7 3 25 2-s2.0-0015165016
3. Thomas L., Lawrence H. S., Discussion of medawar: reactions to homologous tissue antigens in relation to hypersensitivity. Cellular and Humoral Aspects of the Hypersensitivity States 1959 New York, NY, USA Paul Hoeber 529 532
4. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D., IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 410 6832 1107 1111 2-s2.0-0035953308 10.1038/35074122 (Pubitemid 32391043)
5. Smyth M. J., Thia K. Y. T., Street S. E. A., Cretney E., Trapani J. A., Taniguchi M., Kawano T., Pelikan S. B., Crowe N. Y., Godfrey D. I., Differential tumor surveillance by natural killer (NK) and NKT cells. Journal of Experimental Medicine 2000 191 4 661 668 2-s2.0-0034695880 10.1084/jem.191.4.661
6. Smyth M. J., Crowe N. Y., Godfrey D. I., NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. International Immunology 2001 13 4 459 463 2-s2.0-0035071525 (Pubitemid 32288543)
7. Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L. H., Craft J., Yin Z., γ δ T cells provide an early source of interferon γ in tumor immunity. Journal of Experimental Medicine 2003 198 3 433 442 2-s2.0-0042123726 10.1084/jem.20030584 (Pubitemid 36976054)
8. Girardi M., Oppenheim D. E., Steele C. R., Lewis J. M., Glusac E., Filler R., Hobby P., Sutton B., Tigelaar R. E., Hayday A. C., Regulation of cutaneous malignancy by γ δ T cells. Science 2001 294 5542 605 609 2-s2.0-0035914134 10.1126/science.1063916 (Pubitemid 32999559)
9. Noguchi Y., Jungbluth A., Richards E. C., Old L. J., Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proceedings of the National Academy of Sciences of the United States of America 1996 93 21 11798 11801 2-s2.0-0029909109 10.1073/pnas.93.21.11798 (Pubitemid 26347203)
10. van den Broek M. F., Kägi D., Ossendorp F., Toes R., Vamvakas S., Lutz W. K., Melief C. J. M., Zinkernagel R. M., Hengartner H., Decreased tumor surveillance in perforin-deficient mice. Journal of Experimental Medicine 1996 184 5 1781 1790 2-s2.0-0029804782 (Pubitemid 26404469)
11. Enzler T., Gillessen S., Manis J. P., Ferguson D., Fleming J., Alt F. W., Mihm M., Dranoff G., Deficiencies of GM-CSF and interferon γ link inflammation and cancer. Journal of Experimental Medicine 2003 197 9 1213 1219 2-s2.0-0038558189 10.1084/jem.20021258 (Pubitemid 36570077)
12. Auffray C., Sieweke M. H., Geissmann F., Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annual Review of Immunology 2009 27 669 692 2-s2.0-67649404131 10.1146/annurev.immunol.021908. 132557
13. Gordon S., Alternative activation of macrophages. Nature Reviews Immunology 2003 3 23 35 10.1038/nri978 (Pubitemid 37328697)
14. Modolell M., Corraliza I. M., Link F., Soler G., Eichmann K., Reciprocal regulation of the nitric oxide synthase-arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. European The Journal of Immunology 1995 25 4 1101 1104 2-s2.0-0028916297
15. Fairweather D., Cihakova D., Alternatively activated macrophages in infection and autoimmunity. Journal of Autoimmunity 2009 33 3-4 222 230 2-s2.0-71649091697 10.1016/j.jaut.2009.09.012
16. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M., The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology 2004 25 12 677 686 2-s2.0-7644231561 10.1016/j.it.2004.09. 015 (Pubitemid 39457982)
17. Solinas G., Germano G., Mantovani A., Allavena P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. Journal of Leukocyte Biology 2009 86 5 1065 1073 2-s2.0-70350728931 10.1189/jlb.0609385
18. Condeelis J., Pollard J. W., Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006 124 2 263 266 2-s2.0-31044433663 10.1016/j.cell.2006.01.007 (Pubitemid 43121975)
19. Kzhyshkowska J., Mamidi S., Gratchev A., Kremmer E., Schmuttermaier C., Krusell L., Haus G., Utikal J., Schledzewski K., Scholtze J., Goerdt S., Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 2006 107 8 3221 3228 2-s2.0-33645727755 10.1182/blood-2005-07-2843
20. Högger P., Dreier J., Droste A., Buck F., Sorg C., Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). The Journal of Immunology 1998 161 4 1883 1890 2-s2.0-0032529409 (Pubitemid 28387610)
21. Raes G., de Baetselier P., Noël W., Beschin A., Brombacher F., Hassanzadeh G. G., Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. Journal of Leukocyte Biology 2002 71 4 597 602 2-s2.0-0036553909
22. Rodríguez P. C., Ochoa A. C., Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological Reviews 2008 222 1 180 191 2-s2.0-41149148269 10.1111/j.1600-065X.2008.00608.x (Pubitemid 351430370)
23. Sgadari C., Angiolillo A. L., Tosato G., Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996 87 9 3877 3882 2-s2.0-0029922177 (Pubitemid 26129617)
24. Mantovani A., Sica A., Allavena P., Garlanda C., Locati M., Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Human Immunology 2009 70 5 325 330 2-s2.0-65049084189 10.1016/j.humimm.2009.02.008
25. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 2002 23 11 549 555 2-s2.0-0036839143 10.1016/S1471-4906(02)02302-5 (Pubitemid 35223554)
26. Pollard J. W., Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer 2004 4 1 71 78 2-s2.0-0347123433 (Pubitemid 38082155)
27. Sica A., Schioppa T., Mantovani A., Allavena P., Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. European Journal of Cancer 2006 42 6 717 727 2-s2.0-33645991795 10.1016/j.ejca.2006.01.003
28. Raes G., Brys L., Dahal B. K., Brandt J., Grooten J., Brombacher F., Vanham G., Noël W., Bogaert P., Boonefaes T., Kindt A., van den Bergh R., Leenen P. J. M., de Baetselier P., Ghassabeh G. H., Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. Journal of Leukocyte Biology 2005 77 3 321 327 2-s2.0-20044387192 10.1189/jlb.0304212 (Pubitemid 40289561)
29. Geijtenbeek T. B. H., Gringhuis S. I., Signalling through C-type lectin receptors: shaping immune responses. Nature Reviews Immunology 2009 9 7 465 479 2-s2.0-67649840704 10.1038/nri2569
30. Kufe D. W., Mucins in cancer: function, prognosis and therapy. Nature Reviews Cancer 2009 9 12 874 885 2-s2.0-70450247207 10.1038/nrc2761
31. Allavena P., Chieppa M., Bianchi G., Solinas G., Fabbri M., Laskarin G., Mantovani A., Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clinical and Developmental Immunology 2010 2010 10 2-s2.0-79953281969 10.1155/2010/547179 547179
32. Imai Y., Akimoto Y., Mizuochi S., Kimura T., Hirano H., Irimura T., Restricted expression of galactose/N-acetylgalactosamine-specific macrophage C-type lectin to connective tissue and to metastatic lesions in mouse lung. Immunology 1995 86 4 591 598 2-s2.0-0029566268 (Pubitemid 26051811)
33. Solinas G., Schiarea S., Liguori M., Fabbri M., Pesce S., Zammataro L., Pasqualini F., Nebuloni M., Chiabrando C., Mantovani A., Allavena P., Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. The Journal of Immunology 2010 185 1 642 652 2-s2.0-77956212940 10.4049/jimmunol.1000413
34. Bussink A. P., Speijer D., Aerts J. M. F. G., Boot R. G., Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 2007 177 2 959 970 2-s2.0-35548984723 10.1534/genetics.107.075846 (Pubitemid 350005647)
35. Shuhui L., Mok Y. K., Wong W. S. F., Role of mammalian chitinases in asthma. International Archives of Allergy and Immunology 2009 149 4 369 377 2-s2.0-62349090823 10.1159/000205583
36. Cai Y., Kumar R. K., Zhou J., Foster P. S., Webb D. C., Ym1/2 promotes Th2 cytokine expression by inhibiting 12/15(S)-lipoxygenase: identification of a novel pathway for regulating allergic inflammation. The Journal of Immunology 2009 182 9 5393 5399 2-s2.0-66949174488 10.4049/jimmunol.0803874
37. Chang N. C. A., Hung S. I., Hwa K. Y., Kato I., Chen J. E., Liu C. H., Chang A. C., A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. The Journal of Biological Chemistry 2001 276 20 17497 17506 2-s2.0-0035907263 10.1074/jbc.M010417200
38. Lee C. G., da Silva C. A., dela Cruz C. S., Ahangari F., Ma B., Kang M. J., He C. H., Takyar S., Elias J. A., Role of chitin and chitinase/chitinase- like proteins in inflammation, tissue remodeling, and injury. Annual Review of Physiology 2011 73 479 501 2-s2.0-79951776429 10.1146/annurev-physiol-012110- 142250
39. Nair M. G., Cochrane D. W., Allen J. E., Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunology Letters 2003 85 2 173 180 2-s2.0-0037460123 10.1016/S0165-2478(02)00225-0 (Pubitemid 36071573)
40. Holcomb I. N., Kabakoff R. C., Chan B., Baker T. W., Gurney A., Henzel W., Nelson C., Lowman H. B., Wright B. D., Skelton N. J., Frantz G. D., Tumas D. B., Peale F. V. Jr., Shelton D. L., Hébert C. C., FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. The EMBO Journal 2000 19 15 4046 4055 2-s2.0-0034254655 (Pubitemid 30608543)
41. Liu T., Dhanasekaran S. M., Jin H., Hu B., Tomlins S. A., Chinnaiyan A. M., Phan S. H., FIZZ1 stimulation of myofibroblast differentiation. American Journal of Pathology 2004 164 4 1315 1326 2-s2.0-1642357498 (Pubitemid 38387797)
42. Liu T., Jin H., Ullenbruch M., Hu B., Hashimoto N., Moore B., McKenzie A., Lukacs N. W., Phan S. H., Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. The Journal of Immunology 2004 173 5 3425 3431 2-s2.0-4344600287 (Pubitemid 39142053)
43. Teng X., Li D., Champion H. C., Johns R. A., FIZZ1/RELM α a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties. Circulation Research 2003 92 10 1065 1067 2-s2.0-0038390235 10.1161/01.RES.0000073999.07698.33 (Pubitemid 36665851)
44. Schledzewski K., Falkowski M., Moldenhauer G., Metharom P., Kzhyshkowska J., Ganss R., Demory A., Falkowska-Hansen B., Kurzen H., Ugurel S., Geginat G., Arnold B., Goerdt S., Lympathic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macropahages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. Journal of Pathology 2006 209 1 67 77 2-s2.0-33646008309 10.1002/path.1942
45. Kzhyshkowska J., Workman G., Cardó-Vila M., Arap W., Pasqualini R., Gratchev A., Krusell L., Goerdt S., Sage E. H., Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. The Journal of Immunology 2006 176 10 5825 5832 2-s2.0-33646484782
46. Kurte M., López M., Aguirre A., Escobar A., Aguillón J. C., Charo J., Larsen C. G., Kiessling R., Salazar-Onfray F., A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. The Journal of Immunology 2004 173 3 1731 1737 2-s2.0-3242799553 (Pubitemid 38971604)
47. Bak S. P., Alonso A., Turk M. J., Berwin B., Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Molecular Immunology 2008 46 2 258 268 2-s2.0-54349109050 10.1016/j.molimm.2008. 08.266
48. Flavell R. A., Sanjabi S., Wrzesinski S. H., Licona-Limón P., The polarization of immune cells in the tumour environment by TGF β Nature Reviews Immunology 2010 10 8 554 567 2-s2.0-77954951446 10.1038/nri2808
49. Castriconi R., Cantoni C., Chiesa M. D., Vitale M., Marcenaro E., Conte R., Biassoni R., Bottino C., Moretta L., Moretta A., Transforming growth factor β 1 inhibits expression of NKP30 and NKG2d receptors: consequences for the NK-mediated killing of dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2003 100 7 4120 4125 2-s2.0-0037388134 10.1073/pnas.0730640100 (Pubitemid 36418167)
50. Maeda H., Shiraishi A., TGF- β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. The Journal of Immunology 1996 156 1 73 78 2-s2.0-0029671316
51. Beissert S., Hosoi J., Grabbe S., Asahina A., Granstein R. D., IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. The Journal of Immunology 1995 154 3 1280 1286 2-s2.0-0028833639
52. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J., Mantovani A., Autocrine production of IL-10 mediates defective IL-12 production and NF- B activation in tumor-associated macrophages. The Journal of Immunology 2000 164 2 762 767 2-s2.0-0034650833 (Pubitemid 30043699)
53. Lepique A. P., Daghastanli K. R. P., Cuccovia I., Villa L. L., HPV16 tumor associated macrophages suppress antitumor T cell responses. Clinical Cancer Research 2009 15 13 4391 4400 2-s2.0-67650391196 10.1158/1078-0432.CCR- 09-0489
54. Ochoa A. C., Zea A. H., Hernandez C., Rodriguez P. C., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clinical Cancer Research 2007 13 2 721s 726s 2-s2.0-33846886104 10.1158/1078-0432.CCR-06-2197
55. Chang C. I., Liao J. C., Kuo L., Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Research 2001 61 3 1100 1106 2-s2.0-0035113742 (Pubitemid 32174431)
56. Zeisberger S. M., Odermatt B., Marty C., Zehnder-Fjällman A. H. M., Ballmer-Hofer K., Schwendener R. A., Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer 2006 95 3 272 281 2-s2.0-33746926292 10.1038/sj.bjc.6603240 (Pubitemid 44187587)
57. Leek R. D., Lewis C. E., Whitehouse R., Greenall M., Clarke J., Harris A. L., Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Research 1996 56 20 4625 4629 2-s2.0-0029816609 (Pubitemid 26338061)
58. Mäkitie T., Summanen P., Tarkkanen A., Kivelä T., Tumor-infiltrating macrophages (CD68+ cells) and prognosis in malignant uveal melanoma. Investigative Ophthalmology and Visual Science 2001 42 7 1414 1421 2-s2.0-0034994770 (Pubitemid 32520728)
59. Nishie A., Ono M., Shono T., Fukushi J., Otsubo M., Onoue H., Ito Y., Inamura T., Ikezaki K., Fukui M., Iwaki T., Kuwano M., Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clinical Cancer Research 1999 5 5 1107 1113 2-s2.0-0032926784 (Pubitemid 29233226)
60. Koide N., Nishio A., Sato T., Sugiyama A., Miyagawa S. I., Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. American Journal of Gastroenterology 2004 99 9 1667 1674 2-s2.0-4544336555 10.1111/j.1572-0241.2004. 30733.x (Pubitemid 39237489)
61. Hanada T., Nakagawa M., Emoto A., Nomura T., Nasu N., Nomura Y., Prognostic value of tumor-associated macrophage count in human bladder cancer. International Journal of Urology 2000 7 7 263 269 2-s2.0-0033938697 10.1046/j.1442-2042.2000.00190.x (Pubitemid 30440592)
62. Lissbrant I. F., Stattin P., Wikstrom P., Damber J. E., Egevad L., Bergh A., Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. International Journal of Oncology 2000 17 3 445 451 2-s2.0-0034266661
63. Bingle L., Brown N. J., Lewis C. E., The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. Journal of Pathology 2002 196 3 254 265 2-s2.0-0036187615 10.1002/path.1027 (Pubitemid 34189413)
64. Balkwill F., Cancer and the chemokine network. Nature Reviews Cancer 2004 4 7 540 550 2-s2.0-3042822267 (Pubitemid 38868623)
65. Hagemann T., Wilson J., Burke F., Kulbe H., Li N. F., Plüddemann A., Charles K., Gordon S., Balkwill F. R., Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. The Journal of Immunology 2006 176 8 5023 5032 2-s2.0-33645760428
66. Giraudo E., Inoue M., Hanahan D., An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. Journal of Clinical Investigation 2004 114 5 623 633 2-s2.0-4944239035 10.1172/JCI200422087 (Pubitemid 39578752)
67. Krecicki T., Zalesska-Krecicka M., Jelen M., Szkudlarek T., Horobiowska M., Expression of type IV collagen and matrix metalloproteinase-2 (type IV collagenase) in relation to nodal status in laryngeal cancer. Clinical Otolaryngology and Allied Sciences 2001 26 6 469 472 2-s2.0-0035698148 10.1046/j.0307-7772.2001.00503.x (Pubitemid 34088250)
68. Lewis C. E., Pollard J. W., Distinct role of macrophages in different tumor microenvironments. Cancer Research 2006 66 2 605 612 2-s2.0-31544441610 10.1158/0008-5472.CAN-05-4005 (Pubitemid 43165918)
69. Polverini P. J., Leibovich S. J., Effect of macrophage depletion on growth and neovascularization of hamster buccal pouch carcinomas. Journal of Oral Pathology 1987 16 9 436 441 2-s2.0-0023423262
70. Tsutsui S., Yasuda K., Suzuki K., Tahara K., Higashi H., Era S., Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncology Reports 2005 14 2 425 431 2-s2.0-24744454660
71. Ohno S., Ohno Y., Suzuki N., Kamei T., Koike K., Inagawa H., Kohchi C., Soma G. I., Inoue M., Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Research 2004 24 5 C 3335 3342 2-s2.0-6344250782 (Pubitemid 39390949)
72. Lin E. Y., Nguyen A. V., Russell R. G., Pollard J. W., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. Journal of Experimental Medicine 2001 193 6 727 740 2-s2.0-0035911221 10.1084/jem.193.6.727 (Pubitemid 32524466)
73. Öberg A., Samii S., Stenling R., Lindmark G., Different occurrence of CD8+, CD45R0+, and CD68 + immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. International Journal of Colorectal Disease 2002 17 1 25 29 2-s2.0-0036355045 10.1007/s003840100337 (Pubitemid 41398987)
74. Coffelt S. B., Hughes R., Lewis C. E., Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochimica et Biophysica Acta 2009 1796 1 11 18 2-s2.0-68949114117 10.1016/j.bbcan.2009.02.004
75. Wyckoff J., Wang W., Lin E. Y., Wang Y., Pixley F., Stanley E. R., Graf T., Pollard J. W., Segall J., Condeelis J., A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Research 2004 64 19 7022 7029 2-s2.0-4944229701 10.1158/0008-5472.CAN-04-1449 (Pubitemid 39331012)
76. Schoppmann S. F., Lymphangiogenesis, inflammation and metastasis. Anticancer Research 2005 25 6 4503 4511 2-s2.0-28444496283 (Pubitemid 41729504)
77. Fuhrman L. E., Goel A. K., Smith J., Shianna K. V., Aballay A., Nucleolar proteins suppress Caenorhabditis elegans innate immunity by inhibiting p53/CEP-1. PLoS Genetics 2009 5 9 2-s2.0-70349668990 10.1371/journal.pgen. 1000657 e1000657
78. Chelbi-Alix M. K., Quignon F., Pelicano L., Koken M. H. M., de Thé H., Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. Journal of Virology 1998 72 2 1043 1051 2-s2.0-0031907092 (Pubitemid 28116883)
79. García M. A., Collado M., Mũoz-Fontela C., Matheu A., Marcos-Villar L., Arroyo J., Esteban M., Serrano M., Rivas C., Antiviral action of the tumor suppressor ARF. The EMBO Journal 2006 25 18 4284 4292 2-s2.0-33748937018 10.1038/sj.emboj.7601302 (Pubitemid 44435226)
80. Muñoz-Fontela C., Macip S., Martínez-Sobrido L., Brown L., Ashour J., García-Sastre A., Lee S. W., Aaronson S. A., Transcriptional role of p53 in interferon-mediated antiviral immunity. Journal of Experimental Medicine 2008 205 8 1929 1938 2-s2.0-49249135191 10.1084/jem.20080383
81. Muñoz-Fontela C., Garcia M. A., Garcia-Cao I., Collado M., Arroyo J., Esteban M., Serrano M., Rivas C., Resistance to viral infection of super p53 mice. Oncogene 2005 24 18 3059 3062 2-s2.0-18744402474 10.1038/sj.onc.1208477 (Pubitemid 40675538)
82. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T., Honda K., Taniguchi T., Integration of interferon- α / β signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003 424 6948 516 523 2-s2.0-0041662272 10.1038/nature01850 (Pubitemid 36975769)
83. Lavau C., Marchio A., Fagioli M., Jansen J., Falini B., Lebon P., Grosveld F., Pandolfi P. P., Pelicci P. G., Dejean A., The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 1995 11 5 871 876 2-s2.0-0028979594
84. Grötzinger T., Sternsdorf T., Jensen K., Will H., Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). European Journal of Biochemistry 1996 238 2 554 560 2-s2.0-0029894340 (Pubitemid 26191163)
85. Yang C. T., You L., Uematsu K., Yeh C. C., McCormick F., Jablons D. M., p14ARF modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Research 2001 61 16 5959 5963 2-s2.0-0035881594 (Pubitemid 32762521)
86. Pollice A., Nasti V., Ronca R., Vivo M., Lo Iacono M., Calogero R., Calabrò V., la Mantia G., Functional and physical interaction of the human ARF tumor suppressor with tat-binding protein-1. The Journal of Biological Chemistry 2004 279 8 6345 6353 2-s2.0-1342282986 10.1074/jbc.M310957200 (Pubitemid 38248767)
87. Traves P. G., Lopez-Fontal R., Luque A., Hortelano S., The tumor suppressor ARF regulates innate immune responses in mice. The Journal of Immunology 2011 187 12 6527 6538 10.4049/jimmunol.1004070
88. Taura M., Eguma A., Suico M. A., Shuto T., Koga T., Komatsu K., Komune T., Sato T., Saya H., Li J. D., Kai H., p53 regulates toll-like receptor 3 expression and function in human epithelial cell lines. Molecular and Cellular Biology 2008 28 21 6557 6567 2-s2.0-55449105737 10.1128/MCB.01202-08
89. Taura M., Suico M. A., Koyama K., Komatsu K., Miyakita R., Matsumoto C., Kudo E., Kariya R., Goto H., Kitajima S., Takahashi C., Shuto T., Nakao M., Okada S., Kai H., Rb/E2F1 regulates the Iinnate immune receptor toll-like receptor 3 in epithelial cells. Molecular and Cellular Biology 2012 32 8 1581 1590 10.1128/MCB.06454-11
90. Cavenee W. K., Dryja T. P., Phillips R. A., Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983 305 5937 779 784 2-s2.0-0020518746 (Pubitemid 13010953)
91. Chellappan S. P., Hiebert S., Mudryj M., Horowitz J. M., Nevins J. R., The E2F transcription factor is a cellular target for the RB protein. Cell 1991 65 6 1053 1061 2-s2.0-0025905183 10.1016/0092-8674(91)90557-F (Pubitemid 121001693)
92. Shirodkar S., Ewen M., DeCaprio J. A., Morgan J., Livingston D. M., Chittenden T., The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 1992 68 1 157 166 2-s2.0-0026530730 10.1016/0092-8674(92)90214-W
93. Garcia M. A., Gallego P., Campagna M., González-Santamaría J., Martínez G., Marcos-Villar L., Vidal A., Esteban M., Rivas C., Activation of NF- B pathway by virus infection requires Rb expression. PLoS ONE 2009 4 7 2-s2.0-68149097084 10.1371/journal.pone.0006422 e6422
94. Regad T., Chelbi-Alix M. K., Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001 20 49 7274 7286 2-s2.0-0035969127 10.1038/sj.onc.1204854 (Pubitemid 33105016)
95. Pampin M., Simonin Y., Blondel B., Percherancier Y., Chelbi-Alix M. K., Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. Journal of Virology 2006 80 17 8582 8592 2-s2.0-33748636239 10.1128/JVI.00031-06 (Pubitemid 44384869)
96. Regad T., Saib A., Lallemand-Breitenbach V., Pandolfi P. P., de Thé H., Chelbi-Alix M. K., PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. The EMBO Journal 2001 20 13 3495 3505 2-s2.0-0035796503 10.1093/emboj/20.13.3495 (Pubitemid 32634356)
97. Blondel D., Kheddache S., Lahaye X., Dianoux L., Chelbi-Alix M. K., Resistance to rabies virus infection conferred by the PMLIV isoform. Journal of Virology 2010 84 20 10719 10726 2-s2.0-77957192176 10.1128/JVI.01286-10
98. Bonilla W. V., Pinschewer D. D., Klenerman P., Rousson V., Gaboli M., Pandolfi P. P., Zinkernagel R. M., Salvato M. S., Hengartner H., Effects of promyelocytic leukemia protein on virus-host balance. Journal of Virology 2002 76 8 3810 3818 2-s2.0-0036200416 10.1128/JVI.76.8.3810-3818.2002 (Pubitemid 34250546)
99. El Mchichi B., Regad T., Maroui M. A., Rodriguez M. S., Aminev A., Gerbaud S., Escriou N., Dianoux L., Chelbi-Alix M. K., SUMOylation promotes PML degradation during encephalomyocarditis virus infection. Journal of Virology 2010 84 22 11634 11645 2-s2.0-78049519070 10.1128/JVI.01321-10
100. Everett R. D., Chelbi-Alix M. K., PML and PML nuclear bodies: implications in antiviral defence. Biochimie 2007 89 6-7 819 830 2-s2.0-34347348272 10.1016/j.biochi.2007.01.004 (Pubitemid 47008945)
101. Momand J., Wu H. H., Dasgupta G., MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000 242 1-2 15 29 2-s2.0-0033959744 10.1016/S0378-1119(99)00487-4 (Pubitemid 30064488)
102. Haupt Y., Maya R., Kazaz A., Oren M., Mdm2 promotes the rapid degradation of p53. Nature 1997 387 6630 296 299 2-s2.0-0030905284 10.1038/387296a0 (Pubitemid 27220766)
103. Pomerantz J., Schreiber-Agus N., Liégeois N. J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H. W., Cordon-Cardo C., DePinho R. A., The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998 92 6 713 723 2-s2.0-0032549704 10.1016/S0092-8674(00)81400-2 (Pubitemid 28155311)
104. Fuster J. J., Sanz-González S. M., Moll U. M., Andrés V., Classic and novel roles of p53: prospects for anticancer therapy. Trends in Molecular Medicine 2007 13 5 192 199 2-s2.0-34247597764 10.1016/j.molmed.2007. 03.002 (Pubitemid 46687126)
105. Shen Y., Wang X., Guo L., Qiu Y., Li X., Yu H., Xiang H., Tong G., Ma Z., Influenza A virus induces p53 accumulation in a biphasic pattern. Biochemical and Biophysical Research Communications 2009 382 2 331 335 2-s2.0-63549126531 10.1016/j.bbrc.2009.03.018
106. Dharel N., Kato N., Muroyama R., Taniguchi H., Otsuka M., Wang Y., Jazag A., Shao R. X., Chang J. H., Adler M. K., Kawabe T., Omata M., Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology 2008 47 4 1136 1149 2-s2.0-42249102246 10.1002/hep.22176 (Pubitemid 351547900)
107. Mori T., Anazawa Y., Iiizumi M., Fukuda S., Nakamura Y., Arakawa H., Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002 21 18 2914 2918 2-s2.0-0037171938 10.1038/sj/onc/1205459 (Pubitemid 34499391)
108. Uematsu S., Akira S., Toll-like receptors and innate immunity. Journal of Molecular Medicine 2006 84 9 712 725 2-s2.0-33748308787 10.1007/s00109-006- 0084-y (Pubitemid 44328063)
109. Hummer B. T., Li X. L., Hassel B. A., Role for p53 in gene induction by double-stranded RNA. Journal of Virology 2001 75 16 7774 7777 2-s2.0-0034904982 10.1128/JVI.75.16.7774-7777.2001 (Pubitemid 32738040)
110. Hacke K., Rincon-Orozco B., Buchwalter G., Siehler S. Y., Wasylyk B., Wiesmüller L., Rösl F., Regulation of MCP-1 chemokine transcription by p53. Molecular Cancer 2010 9, article 82 2-s2.0-77950943459 10.1186/1476-4598-9-82
111. Huang S., Singh R. K., Xie K., Gutman M., Berry K. K., Bucana C. D., Fidler I. J., Bar-Eli M., Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunology Immunotherapy 1994 39 4 231 238 2-s2.0-0028113476 (Pubitemid 24316764)
112. Kleine-Lowinski K., Rheinwald J. G., Fichorova R. N., Anderson D. J., Basile J., Münger K., Daly C. M., Rösl F., Rollins B. J., Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. International Journal of Cancer 2003 107 3 407 415 2-s2.0-0142059058 10.1002/ijc.11411 (Pubitemid 37266461)
113. Sharpless N. E., INK4a/ARF: a multifunctional tumor suppressor locus. Mutation Research 2005 576 1-2 22 38 2-s2.0-22144489899 10.1016/j.mrfmmm.2004. 08.021 (Pubitemid 40982680)
114. Serrano M., The tumor suppressor protein p16(INK4a). Experimental Cell Research 1997 237 1 7 13 2-s2.0-0031586589 10.1006/excr.1997.3824 (Pubitemid 27528022)
115. Quelle D. E., Zindy F., Ashmun R. A., Sherr C. J., Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995 83 6 993 1000 2-s2.0-0029587551 10.1016/0092-8674(95)90214-7 (Pubitemid 26006540)
116. Stott F. J., Bates S., James M. C., McConnell B. B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K. H., Peters G., The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. The EMBO Journal 1998 17 17 5001 5014 2-s2.0-0032169516 10.1093/emboj/17.17.5001 (Pubitemid 28408466)
117. Weber J. D., Jeffers J. R., Rehg J. E., Randle D. H., Lozano G., Roussel M. F., Sherr C. J., Zambetti G. P., p53-independent functions of the p19(ARF) tumor suppressor. Genes and Development 2000 14 18 2358 2365 2-s2.0-0034665749 10.1101/gad.827300
118. Sugimoto M., Kuo M. L., Roussel M. F., Sherr C. J., Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Molecular Cell 2003 11 2 415 424 2-s2.0-0037291204 10.1016/S1097-2765(03)00057-1 (Pubitemid 36293835)
119. Martelli F., Hamilton T., Silver D. P., Sharpless N. E., Bardeesy N., Rokas M., DePinho R. A., Livingston D. M., Grossman S. R., p19ARF targets certain E2F species for degradation. Proceedings of the National Academy of Sciences of the United States of America 2001 98 8 4455 4460 2-s2.0-0035836772 10.1073/pnas.081061398 (Pubitemid 32294998)
120. Qi Y., Gregory M. A., Li Z., Brousal J. P., West K., Hann S. R., p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 2004 431 7009 712 717 2-s2.0-6044254972 10.1038/nature02958 (Pubitemid 39382620)
121. Kuo M. L., Duncavage E. J., Mathew R., den Besten W., Pei D., Naeve D., Yamamoto T., Cheng C., Sherr C. J., Roussel M. F., Arf induces p53-dependent and -independent antiproliferative genes. Cancer Research 2003 63 5 1046 1053 2-s2.0-0037374474 (Pubitemid 36278437)
122. Bertwistle D., Sugimoto M., Sherr C. J., Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Molecular and Cellular Biology 2004 24 3 985 996 2-s2.0-1642499357 10.1128/MCB.24.3.985-996.2004 (Pubitemid 38112164)
123. Damalas A., Velimezi G., Kalaitzakis A., Liontos M., Papavassiliou A. G., Gorgoulis V., Angelidis C., Loss of p14ARF confers resistance to heat shock- and oxidative stress-mediated cell death by upregulating β -catenin. International Journal of Cancer 2011 128 8 1989 1995 2-s2.0-79951982042 10.1002/ijc.25510
124. González-Navarro H., Abu Nabah Y. N., Vinué A., Andrés-Manzano M. J., Collado M., Serrano M., Andrés V., p19ARF deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. Journal of the American College of Cardiology 2010 55 20 2258 2268 2-s2.0-77951888636 10.1016/j.jacc.2010.01.026
125. Gromley A., Churchman M. L., Zindy F., Sherr C. J., Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice. Proceedings of the National Academy of Sciences of the United States of America 2009 106 15 6285 6290 2-s2.0-65549141147 10.1073/pnas. 0902310106
126. Herranz S., Traves P. G., Luque A., Hortelano S., Role of the tumor suppressor ARF in macrophage polarization. Enhancement of the M2 phenotype in ARF-deficient mice. OncoImmunology 2012 1 8 1227 1238 10.4161/onci.21207
127. Chen M., Capps C., Willerson J. T., Zoldhelyi P., E2F-1 regulates nuclear factor- B activity and cell adhesion: potential antiinflammatory activity of the transcription factor E2F-1. Circulation 2002 106 21 2707 2713 2-s2.0-0037137298 10.1161/01.CIR.0000038706.30661.86 (Pubitemid 35364926)
128. Fang F., Wang Y., Li R., Zhao Y., Guo Y., Jiang M., Sun J., Ma Y., Ren Z., Tian Z., Wei F., Yang D., Xiao W., Transcription factor E2F1 suppresses dendritic cell maturation. The Journal of Immunology 2010 184 11 6084 6091 2-s2.0-77953408779 10.4049/jimmunol.0902561
129. Kamijo T., Zindy F., Roussel M. F., Quelle D. E., Downing J. R., Ashmun R. A., Grosveld G., Sherr C. J., Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF). Cell 1997 91 5 649 659 2-s2.0-0030728468 (Pubitemid 27513656)
130. Kamijo T., Bodner S., van de Kamp E., Randle D. H., Sherr C. J., Tumor spectrum in ARF-deficient mice. Cancer Research 1999 59 9 2217 2222 2-s2.0-0033135110 (Pubitemid 29217688)
131. Kawagishi H., Nakamura H., Maruyama M., Mizutani S., Sugimoto K., Takagi M., Sugimoto M., ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. Cancer Research 2010 70 11 4749 4758 2-s2.0-77953168825 10.1158/0008-5472.CAN-10-0368
132. Fatyol K., Szalay A. A., The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1 α (HIF-1 α) and inhibits HIF-1-mediated transcription. The Journal of Biological Chemistry 2001 276 30 28421 28429 2-s2.0-0035958932 10.1074/jbc.M102847200
133. Zerrouqi A., Pyrzynska B., Febbraio M., Brat D. J., Van Meir E. G., P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. Journal of Clinical Investigation 2012 122 4 1283 1295 10.1172/JCI38596